Next Article in Journal / Special Issue
Diet in Scleroderma: Is There a Need for Intervention?
Previous Article in Journal
SARS-CoV-2 Infection Prevalence in the Population of South-Eastern Poland
Previous Article in Special Issue
Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Article

Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis

1
Department of Dermatology, Ordensklinikum Linz Elisabethinen, 4020 Linz, Austria
2
Faculty of Medicine, Johannes Kepler University Linz, 4040 Linz, Austria
3
Institute for Analytical and General Chemistry, Johannes Kepler University Linz, 4040 Linz, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Cosimo Bruni
Diagnostics 2021, 11(11), 2116; https://doi.org/10.3390/diagnostics11112116
Received: 10 September 2021 / Revised: 3 November 2021 / Accepted: 5 November 2021 / Published: 15 November 2021
(This article belongs to the Special Issue Advances in Identification and Management of Systemic Sclerosis)
Systemic sclerosis (SSc) is an autoimmune disease with fibrosis of the skin and/or internal organs, causing a decrease in quality of life and survival. There is no causative therapy, and the pathophysiology of the SSc remains unclear. Studies showed that lipid metabolism was relevant for autoimmune diseases, but little is known about the role of lipids in SSc. In the present study, we sought to explore the phospholipid profile of SSc by using the lipidomics approach. We also aimed to analyze lipidomics results for different clinical manifestations of SSc. Experiments were performed using high-performance liquid chromatography coupled to mass spectrometry for the lipidomic profiling of plasma samples from patients with SSc. Our study showed, for the first time, significant changes in the level of phospholipids such as plasmalogens and sphingomyelins from the plasma of SSc patients as compared to controls. Phosphatidylcholine plasmalogens species and sphingomyelins were significantly increased in SSc patients as compared to controls. Our results also demonstrated a significant association of changes in the metabolism of phospholipids (phosphatidylcholine and phosphatidylethanolamine plasmalogens species and sphingomyelins) with different clinical manifestations of SSc. Further lipidomic studies might lead to the detection of lipids as new biomarkers or therapeutic targets of SSc. View Full-Text
Keywords: systemic sclerosis; lipidomics; skin fibrosis; lung fibrosis; calcinosis cutis; digital ulcers; sicca; plasmalogens; sphingomyelin; phospholipids systemic sclerosis; lipidomics; skin fibrosis; lung fibrosis; calcinosis cutis; digital ulcers; sicca; plasmalogens; sphingomyelin; phospholipids
Show Figures

Figure 1

MDPI and ACS Style

Geroldinger-Simić, M.; Bögl, T.; Himmelsbach, M.; Sepp, N.; Buchberger, W. Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis. Diagnostics 2021, 11, 2116. https://doi.org/10.3390/diagnostics11112116

AMA Style

Geroldinger-Simić M, Bögl T, Himmelsbach M, Sepp N, Buchberger W. Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis. Diagnostics. 2021; 11(11):2116. https://doi.org/10.3390/diagnostics11112116

Chicago/Turabian Style

Geroldinger-Simić, Marija, Thomas Bögl, Markus Himmelsbach, Norbert Sepp, and Wolfgang Buchberger. 2021. "Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis" Diagnostics 11, no. 11: 2116. https://doi.org/10.3390/diagnostics11112116

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop